Host: |
Goat |
Applications: |
Pep-ELISA/WB/IHC |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-RNF7 (Internal) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
Peptide ELISA: antibody detection limit dilution 1:8000.WB: Approx 11kDa band observed in Human Human Heart lysates (calculated MW of 12.7kDa according to NP_055060.1). Recommended concentration: 1-3µg/ml.An additional band of 28kDa was consiste |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
RNF7 |
Gene ID: |
9616 |
Uniprot ID: |
RBX2_HUMAN |
Immunogen Region: |
Internal |
Accession Number: |
NP_055060.1 |
Specificity: |
This antibody is expected to recognize isoform 1 (NP_055060.1). |
Immunogen Sequence: |
DACLRCQAENKQE |
Post Translational Modifications | Phosphorylation at Thr-10 by CK2 promotes its degradation by the proteasome. |
Function | Catalytic component of multiple cullin-5-RING E3 ubiquitin-protein ligase complexes (ECS complexes), which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. It is thereby involved in various biological processes, such as cell cycle progression, signal transduction and transcription. The functional specificity of the E3 ubiquitin-protein ligase ECS complexes depend on the variable SOCS box-containing substrate recognition component. Within ECS complexes, RNF7/RBX2 recruits the E2 ubiquitination enzyme to the complex via its RING-type and brings it into close proximity to the substrate. Catalytic subunit of various SOCS-containing ECS complexes, such as the ECS(SOCS7) complex, that regulate reelin signaling by mediating ubiquitination and degradation of DAB1. The ECS(SOCS2) complex mediates the ubiquitination and subsequent proteasomal degradation of phosphorylated EPOR and GHR. Promotes ubiquitination and degradation of NF1, thereby regulating Ras protein signal transduction. As part of the ECS(ASB9) complex, catalyzes ubiquitination and degradation of CKB. The ECS(SPSB3) complex catalyzes ubiquitination of nuclear CGAS. As part of some ECS complex, catalyzes 'Lys-11'-linked ubiquitination and degradation of BTRC. ECS complexes and ARIH2 collaborate in tandem to mediate ubiquitination of target proteins.ARIH2 mediating addition of the first ubiquitin on CRLs targets. Specifically catalyzes the neddylation of CUL5 via its interaction with UBE2F. Does not catalyze neddylation of other cullins (CUL1, CUL2, CUL3, CUL4A or CUL4B). May play a role in protecting cells from apoptosis induced by redox agents. Isoform 2: Inactive. (Microbial infection) Following infection by HIV-1 virus, catalytic component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex) hijacked by the HIV-1 Vif protein, which catalyzes ubiquitination and degradation of APOBEC3F and APOBEC3G. |
Protein Name | Ring-Box Protein 2Rbx2Ckii Beta-Binding Protein 1Ckbbp1Ring Finger Protein 7Regulator Of Cullins 2Sensitive To Apoptosis Gene Protein |
Database Links | Reactome: R-HSA-8951664Reactome: R-HSA-9705462Reactome: R-HSA-983168 |
Cellular Localisation | CytoplasmNucleus |
Alternative Antibody Names | Anti-Ring-Box Protein 2 antibodyAnti-Rbx2 antibodyAnti-Ckii Beta-Binding Protein 1 antibodyAnti-Ckbbp1 antibodyAnti-Ring Finger Protein 7 antibodyAnti-Regulator Of Cullins 2 antibodyAnti-Sensitive To Apoptosis Gene Protein antibodyAnti-RNF7 antibodyAnti-RBX2 antibodyAnti-ROC2 antibodyAnti-SAG antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance